CIPLA.NS - Cipla Limited Stock Price & Dividend Safety Sector: Healthcare | Exchange: National Stock Exchange of India Current Price & Safety Score Price: 1,355.00 INR StockBonds Safety Grade: Altman Z-Score (Bankruptcy Risk): 0.00 StockBond Score: -1.26 Company Description Cipla Limited along with its associated entities operates as a global pharmaceutical enterprise specializing in the creation and distribution of a wide array of medicinal products Its extensive portfolio includes both active pharmaceutical ingredients APIs and a diverse range of finished formulations addressing numerous therapeutic areas such as cardiovascular diseases metabolic disorders HIV respiratory conditions urology oncology pediatric health infectious diseases critical care hepatitis womens health ophthalmology and neuropsychiatry The company maintains a strong focus on respiratory treatments offering various inhalers nasal sprays injectables and biosimilars Cipla has also forged significant partnerships including a licensing arrangement with Merck Co Inc for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir and a separate license agreement with Eli Lilly and Company for baricitinib indicated for COVID19 Furthermore it collaborates with Dr Reddys Laboratories Ltd Sun Pharmaceutical Industries Limited Emcure Pharmaceuticals Limited and Torrent Pharmaceuticals Limited for Molnupiravirs clinical trials Established in 1935 Ciplas corporate headquarters are located in Mumbai India